Post-earnings recap
Reported
Tue, May 2, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a strong EPS figure, significantly beating expectations. However, the stock fell by 0.95% in reaction, likely due to the lack of revenue information and guidance. Investors may be cautious as the company did not provide a clear outlook for the future.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.45 | N/A | +169.12% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism regarding their financial performance. They noted the significant EPS surprise but did not provide further details on revenue.
Management highlighted the strong EPS performance despite not providing revenue figures.
They emphasized ongoing commitment to their pipeline and future projects.